CN111808965A - Characteristic lincRNA expression profile combination and early prediction method of renal clear cell carcinoma - Google Patents
Characteristic lincRNA expression profile combination and early prediction method of renal clear cell carcinoma Download PDFInfo
- Publication number
- CN111808965A CN111808965A CN202010775121.9A CN202010775121A CN111808965A CN 111808965 A CN111808965 A CN 111808965A CN 202010775121 A CN202010775121 A CN 202010775121A CN 111808965 A CN111808965 A CN 111808965A
- Authority
- CN
- China
- Prior art keywords
- lincrna
- prediction
- sample
- expression
- characteristic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
The invention discloses a characteristic lincRNA expression profile combination and an early prediction method of renal clear cell carcinoma, wherein a nucleotide probe sequence of lincRNA is shown as SEQ ID NO. 1-26. The method for evaluating the early risk of the renal clear cell carcinoma based on the lincRNA expression profile combination characteristics has high precision and accuracy (the area AUC under the ROC curve is 0.964). The early stage morbidity probability of the renal clear cell carcinoma is calculated and given through a support vector machine model only by acquiring the relative expression quantity of the 26 lincRNAs, and the early stage morbidity probability can be used as a reference basis for early stage prediction of the renal clear cell carcinoma.
Description
Technical Field
The invention belongs to the field of biotechnology and medicine, and particularly relates to a characteristic lincRNA expression profile combination and an early prediction method of renal clear cell carcinoma.
Background
Renal clear cell carcinoma (kidney renal clear cell carcinoma) accounts for approximately 70% -80% of renal cell carcinoma. Renal clear cell carcinoma often has no symptoms in the early stage, or has general symptoms such as fever and hypodynamia, and the early diagnosis is difficult. Global Burden of Disease (GBD) data shows that over 210 million people with renal cancer worldwide in 2017, with about 27 million people in china. The number of deaths of kidney cancer in 2017 worldwide is about 14 ten thousand, accounting for 0.25% of the total deaths. The number of the death patients in 2017 years in China is about 1.7 ten thousand, and accounts for 0.16 percent of the total death number. Statistics show that the prevalence and mortality of kidney cancer continues to increase worldwide from 1990 to 2017. In China, the prevalence rate and the death rate of the renal cancer are relatively stable in the last decade.
A Support Vector Machine (SVM) is a generalized linear classifier that performs binary classification on data in a supervised learning manner, and a decision boundary of the SVM is a maximum edge distance hyperplane for solving a learning sample. The SVM model represents instances as points in space, so that the mapping is such that instances of the individual classes are separated by as wide an apparent interval as possible. The new instances are then mapped to the same space and the categories are predicted based on which side of the interval they fall on. When the training data is linearly separable, the SVM is classified by hard interval maximization learning. When the training data is linearly non-separable, the SVM is classified by using a kernel technique and soft interval maximization learning. SVMs are powerful for medium-sized data sets with similar meaning of features and are also suitable for small data sets. In general, the prediction effect is good for the SVM data set with the sample size less than 1 ten thousand. SVM has a wide range of applications in disease diagnosis, tumor classification, tumor gene recognition, and the like.
Early diagnosis of tumors has been a difficult problem in the medical community. The existing early diagnosis methods mostly observe the expression level of a certain marker or a class of markers, and the ideal diagnosis effect is difficult to achieve. Since the expression profiles of these markers in tumor patients and normal populations partially overlap, it is difficult to define a cut-off for the markers that better separates tumor patients from normal populations. Therefore, the use of multiple marker expression signature combinations may be an effective method for early diagnosis of tumors. Long-stranded intergenic non-coding RNA (lincRNA) is a type of non-coding single-stranded RNA molecule with a length greater than 200 nucleotides located in the intergenic non-coding sequence. lincRNA has no coding potential and is not conserved between different species. Research shows that lincRNA is involved in the expression regulation of multiple genes, and the lincRNA is relatively stable in expression in a human body and easy to detect. Since the expression distribution of individual lincRNA molecules in tumor and normal human populations overlap, it is difficult to define a critical value for early prediction.
Therefore, there is a need to establish a predictive model of a more stable combination of multiple differential lincRNA expression profiles that contributes to the early prediction of renal clear cell carcinoma.
Disclosure of Invention
In view of the above, the present invention provides a combination of characteristic lincRNA expression profiles and a method for early stage renal clear cell carcinoma prediction, which can accurately predict the stage I/II renal clear cell carcinoma.
In order to solve the technical problem, the invention discloses a characteristic lincRNA expression profile combination, which comprises AC002070.1, AC007114.1, AC015813.1, AC091271.1, AC091563.1, AC120049.1, AL355338.1, AP002360.1, C22orf34, CYTOR, DNAJC3-DT, EPB41L4A-AS1, FGF14-AS2, IQCH-AS1, LINC00240, LINC01503, LINC02381, LINC02615, MIR210HG, MIR4435-2HG, MUC20-OT1, PSMB8-AS1, PSMG3-AS1, SNHG15, URB1-AS1 and ZNF667-AS1, wherein the nucleotide probe sequence of the combination is shown in SEQ ID NO. 1-26.
The invention discloses an early renal clear cell carcinoma prediction method based on the characteristic lincRNA expression profile combination, which comprises the following steps of:
step 2, selecting characteristic lincRNA expression data, and carrying out data standardization on each sample;
step 3, constructing an early prediction model for the standardized data by using a support vector machine;
step 4, carrying out early prediction according to the expression level of lincRNA (lincRNA) of the patient characteristics;
the method is for non-disease diagnostic and therapeutic purposes.
Optionally, the characteristic lincRNA for obtaining stable differential expression of the patient in the early stage of renal clear cell carcinoma in the step 1 is specifically:
step 1.1, downloading transcriptome Data and clinical Data of tumor tissues and tissues beside renal clear cell carcinoma patients from a Genomic Data common Data Portal database, obtaining tumor tissue gene expression profile read counts values of the renal clear cell carcinoma patients, and carrying out logarithmic conversion;
step 1.2, selecting lincRNA with certain expression abundance, namely, the readcounts of the lincRNA in all samples are more than or equal to 10, taking the logarithm of the readcounts of all the lincRNA, setting the total number of the samples as n, taking the total number of the screened lincRNA as m, v as the readcounts of the lincRNA, and u as an expression value after taking the logarithm, wherein the readcounts have the expression abundance;
uij＝log2vij，i∈(1，n)，j∈(1，m) (1)
wherein i is the sample number, j is the lincRNA number, uijExpression value after taking logarithm of ith sample and jth lincRNA number, vijRead counts values for the ith sample, jth lincRNA number;
step 1.3, selecting renal clear cell carcinoma patients with disease stages of I and II, recording the patients as renal clear cell carcinoma early-stage patients, and recording the total number of the renal clear cell carcinoma early-stage patients as n';
step 1.4, selecting the lincRNA stably expressed in the tumor sample and the normal sample, namely the lincRNA with the coefficient of variation smaller than 0.2 in the tumor sample and the normal sample, setting mu as the expression mean value of the lincRNA in all samples, setting sigma as the standard deviation, and calculating the coefficient of variation according to the formula:
wherein j is the lincRNA number, cvIs the coefficient of variation, cvjCoefficient of variation, σ, for the j-th samplejStandard deviation for jth lincRNA numbering, μjThe expression average of lincRNA numbered for the jth lincRNA, set as m1For the total number of stably expressed lincrnas, the following are:
step 1.5, selecting lincRNA which is differentially expressed in a tumor sample and a normal sample; the log-taken expression values were used to calculate the log-taken fold change f of the lincrnas in tumor and normal samples, and the formula is:
wherein j is the lincRNA number, fjFold change for jth lincRNA numbering,. mu.1jExpression mean, μ, of tumor samples numbered for jth lincRNA2jThe expression mean of the normal sample numbered for the jth lincRNA;
the expression difference of lincRNA in tumor and normal samples was then compared using independent sample t-test, which was formulated as:
wherein n is1Is the number of tumor samples, n2Is a normal number of samples, mu1Mean expression of lincRNA in tumor samples, μ2Is the mean value of the expression of lincRNA in a normal sample,
the variance of lincRNA in the tumor sample,
lincRNA variance for normal samples;
correcting the p values obtained by all t tests by using a False Discovery Rate (FDR), wherein q is a value corrected by the FDR, and r is a p value in m1The sequenced positions in each lincRNA are:
wherein j is the lincRNA number;
finally, lincRNA with the absolute value of the fold change f larger than 1 and the q value smaller than or equal to 0.05 after FDR correction is selected and marked as characteristic lincRNA, and the total number of the characteristic lincRNA is set as m2Then, there are:
m2＝m1{|fj|≥1，qj≤0.05}，j∈(1，m1) (7)
optionally, the characteristic lincRNA expression data in step 2 is selected, and data normalization is performed on each sample, wherein the formula is as follows:
wherein i is the sample number, j is the characteristic lincRNA number,. mu.iThe mean, σ, of all characteristic lincRNA expression of the ith sampleiFor all characteristic lincRNA standard deviations, u, of the i-th sampleijTo take the characteristic lincRNA expression value after log, uij' is the normalized lincRNA value.
Optionally, the step 3 of constructing an early prediction model for the normalized data by using a support vector machine specifically includes:
step 3.1, grouping all samples, dividing 80% of all samples into a training set and a verification set, and dividing the rest 20% of all samples into a test set; the training set and the verification set are used for 5-fold cross verification, namely the training set and the verification set are divided into 5 groups which are equal, one group is used as the verification set in sequence, and the other 4 groups are used as the training set; parameters are given, a training set is used for constructing a model, and a verification set is used for checking the accuracy of the model;
step 3.2, optimal parameter screening, wherein the parameter gamma in the SVM controls the width of a Gaussian kernel, C is a regularization parameter and limits the importance of each point, and a parameter grid is set as:
gamma＝[0.001，0.01，0.1，1，10，100](9)
C＝[0.001，0.01，0.1，1，10，100](10)
in the cross validation, a model is constructed by sequentially using the combination of every two parameters gamma and C, then a validation set is used for checking the accuracy of the model, for each parameter combination, 1 accuracy is generated in each validation of 5-fold cross validation, 5 accuracies are generated by carrying out 5 times of validation in total, and the parameter combination with the highest average accuracy of the 5 verifications is selected as the optimal parameter;
3.3, constructing a model by using the optimal parameters and data of the training set and the verification set, and finally evaluating the model by using the test set, wherein evaluation indexes comprise accuracy (accuracy), accuracy (precision), recall (call), specificity (specificity), F1 score (F1 score), Matthews Correlation Coefficient (MCC) and area under the Receiver Operating Curve (ROC) (AUC); in the test set, defining the tumor count as True Positive (TP), the tumor count as normal but predicted as False Positive (FP), the tumor count as true but predicted as normal False Negative (FN), the tumor count as normal but predicted as True Negative (TN); the above evaluation index calculation formula is:
the accuracy, recall, specificity, F1 score and AUC of the above assessment indices returned values between (0, 1); the higher the accuracy is, the higher the overall prediction efficiency of the model is; higher accuracy indicates that the class I error is smaller; higher recall indicates that a class II error is being made smaller; the high specificity indicates that few negative examples are mixed in the samples predicted to be positive examples; the F1 score is a comprehensive index and is a harmonic average of the accuracy rate and the recall rate; MCC is the correlation coefficient between observed and predicted binary classifications, returning a value between (-1, 1), where 1 represents perfect prediction, 0 represents no better than random prediction, -1 represents a complete disparity between prediction and observation; the higher AUC indicates the higher probability of the positive case predicted by the classifier, so that the closer the indexes are to 1, the better the overall prediction effect of the model is;
and 3.4, if the evaluation indexes are all larger than 0.9, the model has a better prediction effect, and then all data are used and the optimal parameter combination is used for constructing a final prediction model.
Optionally, the early prediction in step 4 according to the expression level of lincRNA characteristic to the patient is specifically as follows:
step 4.1, standardizing the characteristic lincRNA expression data of the prediction sample, setting u as the characteristic lincRNA expression value of the prediction sample, setting mu as the average value of the characteristic lincRNA expression of the prediction sample, and setting sigma as the standard deviation of the characteristic lincRNA of the prediction sample, wherein the formula is as follows:
wherein j is the characteristic lincRNA numbering, uj' is the normalized lincRNA value;
and 4.2, substituting the normalized lincRNA value of the prediction sample into the final prediction to predict, wherein the prediction result is 1 to indicate that the patient has renal clear cell carcinoma, and the prediction result is 0 to indicate that the patient is normal.
Compared with the prior art, the invention can obtain the following technical effects:
1) the prediction speed is high: the prediction model constructed by the invention can be used for rapidly predicting large-scale samples, and the prediction time of 100 samples only needs a few seconds.
2) The accuracy is high: the prediction model constructed by the method has high prediction accuracy and accuracy, both of which reach over 90 percent, and the area AUC under the ROC curve is 0.964.
3) Platform heterogeneity impact is minor: since there is a large difference in lincRNA expression values determined for different analysis platforms, the present invention predicts the use of normalized characteristic lincRNA expression values and is therefore less affected by platform heterogeneity.
Of course, it is not necessary for any one product in which the invention is practiced to achieve all of the above-described technical effects simultaneously.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the invention and not to limit the invention. In the drawings:
FIG. 1 is a flow chart of data screening and model building according to the present invention;
FIG. 2 is a cross-validation parameter optimization process for a support vector machine model according to the present invention;
FIG. 3 is a diagram of a test set evaluation index for a support vector machine model according to the present invention;
FIG. 4 is a support vector machine model test set ROC curve of the present invention.
Detailed Description
The following embodiments are described in detail with reference to the accompanying drawings, so that how to implement the technical features of the present invention to solve the technical problems and achieve the technical effects can be fully understood and implemented.
The invention also discloses a renal clear cell carcinoma early stage prediction method based on the combination of characteristic lincRNA expression profiles, which can accurately predict the I/II stage of renal clear cell carcinoma and comprises the following steps:
step 1.1, downloading transcriptome Data and clinical Data of tumor tissues and tissues beside renal clear cell carcinoma patients from a Genomic Data common Data Portal database, obtaining tumor tissue gene expression profile read counts values of the renal clear cell carcinoma patients, and carrying out logarithmic conversion;
and 1.2, selecting the lincRNA with certain expression abundance, namely readcounts of the lincRNA in all samples are more than or equal to 10. Taking the logarithm of the read counts of all the lincRNAs, setting the total number of samples as n, setting the total number of the screened lincRNAs as m, setting v as the read counts of the lincRNAs, and setting u as the expression value after taking the logarithm, wherein the number of the read counts is m;
uij＝log2vij，i∈(1，n)，j∈(1，m) (1)
wherein i is the sample number, j is the lincRNA number, uijExpression value after taking logarithm of ith sample and jth lincRNA number, vijThe read counts number for the ith sample, jth lincRNA number.
Step 1.3, selecting renal clear cell carcinoma patients with disease stages of I and II, recording the patients as renal clear cell carcinoma early-stage patients, and recording the total number of the renal clear cell carcinoma early-stage patients as n';
step 1.4, selecting the lincRNA stably expressed in the tumor sample and the normal sample, namely the lincRNA with the coefficient of variation smaller than 0.2 in the tumor sample and the normal sample, setting mu as the expression mean value of the lincRNA in all samples, setting sigma as the standard deviation, and calculating the coefficient of variation according to the formula:
wherein j is the lincRNA number, cvIs the coefficient of variation, cvjCoefficient of variation, σ, for the j-th samplejStandard deviation for jth lincRNA numbering, μjThe expression average of lincRNA numbered for the jth lincRNA, set as m1For the total number of stably expressed lincrnas, the following are:
step 1.5, lincRNA differentially expressed in tumor and normal samples was selected. The log-taken expression values were used to calculate the log-taken fold change f of the lincrnas in tumor and normal samples, and the formula is:
wherein j is the lincRNA number, fjFold change for jth lincRNA numbering,. mu.1jExpression mean, μ, of tumor samples numbered for jth lincRNA2jThe expression mean of the normal sample numbered for the jth lincRNA.
The expression difference of lincRNA in tumor and normal samples was then compared using independent sample t-test, which was formulated as:
wherein n is1Is the number of tumor samples, n2Is a normal number of samples, mu1Mean expression of lincRNA in tumor samples, μ2Is the mean value of the expression of lincRNA in a normal sample,
the variance of lincRNA in the tumor sample,
is the lincRNA variance of normal samples.
Correcting the p values obtained by all t tests by using a False Discovery Rate (FDR), wherein q is a value corrected by the FDR, and r is a p value in m1The sequenced positions in each lincRNA are:
wherein j is the lincRNA number.
Finally, lincRNA with the absolute value of the fold change f larger than 1 and the q value smaller than or equal to 0.05 after FDR correction is selected and marked as characteristic lincRNA, and the total number of the characteristic lincRNA is set as m2Then, there are:
m2＝m1{|fj|≥1，qj≤0.05}，j∈(1，m1) (7)
step 2, selecting characteristic lincRNA expression data, and carrying out data standardization on each sample, wherein the formula is as follows:
where i is the sample number and j is the characteristic lincRNA number. Mu.siThe mean, σ, of all characteristic lincRNA expression of the ith sampleiFor all characteristic lincRNA standard deviations, u, of the i-th sampleijTo take the characteristic lincRNA expression value after log, uij' is the normalized lincRNA value.
Step 3, constructing an early prediction model for the standardized data by using a support vector machine, specifically:
and 3.1, grouping all samples. 80% of all samples are divided into training set + validation set, and the remaining 20% are divided into test set. The training set and the verification set are used for 5-fold cross validation, namely the training set and the verification set are divided into 5 groups which are equal, one group is used as the verification set in sequence, and the other 4 groups are used as the training set. Given the parameters, the training set is used to construct the model, and the validation set is used to verify the accuracy of the model.
And 3.2, screening the optimal parameters. The parameter gamma in the SVM controls the width of the Gaussian kernel, and C is a regularization parameter, limiting the importance of each point. The parameter grid is set as:
gamma＝[0.001，0.01，0.1，1，10，100](9)
C＝[0.001，0.01，0.1，1，10，100](10)
in cross-validation, the model is constructed using a combination of every two parameters gamma and C in turn, and then the validation set is used to verify the model accuracy. For each parameter combination, each validation of 5-fold cross-validation yielded 1 accuracy, and a total of 5 validations yielded 5 accuracies. And selecting the parameter combination with the highest average accuracy of 5 times of verification as the optimal parameter.
And 3.3, constructing a model by using the optimal parameters and the data of the training set and the verification set, and finally evaluating the model by using the test set. The evaluation index includes accuracy (accuracy), accuracy (precision), recall (call), specificity (specificity), F1 score (F1 score), Mathematic Correlation Coefficient (MCC), and area under the subject operating curve (ROC) (AUC). In the test set, the tumor counts are defined as True Positive (TP), normal but predicted tumor counts as False Positive (FP), tumor counts as False Negative (FN), and normal and predicted as True Negative (TN). The above evaluation index calculation formula is:
the accuracy, recall, specificity, F1 score and AUC returned values between (0, 1) in the above evaluation indices. The higher the accuracy is, the higher the overall prediction efficiency of the model is; higher accuracy indicates that the class I error is smaller; higher recall indicates that a class II error is being made smaller; the high specificity indicates that few negative examples are mixed in the samples predicted to be positive examples; the F1 score is a comprehensive index and is a harmonic average of the accuracy rate and the recall rate; MCC is the correlation coefficient between observed and predicted binary classifications, returning a value between (-1, 1), where 1 represents perfect prediction, 0 represents no better than random prediction, -1 represents a complete disparity between prediction and observation; a higher AUC indicates a higher probability of a positive instance being predicted by the classifier. Therefore, the closer the above index is to 1, the better the prediction effect of the entire model is.
And 3.4, if the evaluation indexes are all larger than 0.9, the model has a better prediction effect. The final prediction model is constructed with the optimal parameter combinations using all the data.
And 4, carrying out early prediction according to the expression level of the lincRNA characteristic of the patient, specifically comprising the following steps:
step 4.1, standardizing the characteristic lincRNA expression data of the prediction sample, setting u as the characteristic lincRNA expression value of the prediction sample, setting mu as the average value of the characteristic lincRNA expression of the prediction sample, and setting sigma as the standard deviation of the characteristic lincRNA of the prediction sample, wherein the formula is as follows:
wherein j is the characteristic lincRNA numbering，uj' is the normalized lincRNA value.
And 4.2, substituting the normalized lincRNA value of the prediction sample into the final prediction for prediction. A prediction of 1 indicates the presence of clear cell renal carcinoma, and a prediction of 0 indicates normal.
Example 1
A method for early prediction of renal clear cell carcinoma based on a combination of characteristic lincRNA expression profiles, comprising the steps of:
Step 1.1, downloading transcriptome Data and clinical Data of tumor tissues and tissues beside renal clear cell carcinoma patients from a Genomic Data common Data Portal database, obtaining tumor tissue gene expression profile read counts values of the renal clear cell carcinoma patients, and carrying out logarithmic conversion.
Step 1.2, lincRNA with certain expression abundance is selected, namely readcounts of the lincRNA in all samples are more than or equal to 10, and the detailed formula (1) is shown.
And 1.3, selecting patients with renal clear cell carcinoma with disease stages of I and II, wherein the patients are described in formulas (2) to (3) in detail, and recording the patients as early-stage renal clear cell carcinoma patients.
And step 1.4, selecting the stably expressed lincRNA in the tumor sample and the normal sample, namely the lincRNA with the coefficient of variation smaller than 0.2 in the tumor sample and the normal sample.
Step 1.5, lincRNA differentially expressed in tumor and normal samples were selected, as detailed in formulas (4) - (7). Is designated as characteristic lincRNA.
Through the screening, 26 lincRNA characteristic of renal clear cell carcinoma are finally obtained, and the characteristics are shown in Table 1. The nucleotide probe sequences of the lincRNA characteristic of 26 renal clear cell carcinomas are shown in Table 2.
TABLE 1 characteristics of renal clear cell carcinoma lincRNA
TABLE 2 nucleotide Probe sequences for lincRNA characteristic of renal clear cell carcinoma
And 2, carrying out data standardization on each sample, wherein the details are shown in a formula (8).
And 3, constructing an early diagnosis model for the standardized data by using a support vector machine.
And 3.1, grouping all samples. 80% of all samples are divided into training set + validation set, and the remaining 20% are divided into test set. The training set and the verification set are used for 5-fold cross validation, namely the training set and the verification set are divided into 5 groups which are equal, one group is used as the verification set in sequence, and the other 4 groups are used as the training set. Given the parameters, the training set is used to construct the model, and the validation set is used to verify the accuracy of the model. See figure 1 for details.
And 3.2, screening the optimal parameters. The SVM parameter grid is set by formulas (9) - (10). In cross-validation, the model is constructed using a combination of every two parameters gamma and C in turn, and then the validation set is used to verify the model accuracy. For each parameter combination, each validation of 5-fold cross-validation yielded 1 accuracy, and a total of 5 validations yielded 5 accuracies. And selecting the parameter combination with the highest average accuracy of 5 times of verification as the optimal parameter. Fig. 2 shows the cross-validation parameter optimization process, where the model cross-validation accuracy is highest when the parameter gamma is 0.001 and the parameter C is 100: 1.000. the optimal parameters of the model are therefore: gamma is 0.001 and C is 100.
And 3.3, constructing a model by using the optimal parameters and the data of the training set and the verification set, and finally evaluating the model by using the test set. The evaluation index includes accuracy (accuracy), accuracy (precision), recall (call), specificity (specificity), F1 score (F1 score), Mathematic Correlation Coefficient (MCC), and area under the subject operating curve (ROC) (AUC). The evaluation index is described in detail in formulas (11) to (17).
Step 3.4, fig. 3 shows accuracy, recall, specificity, F1 score and MCC in the above evaluation indexes, all of which 6 indexes are greater than 0.92; FIG. 4 shows the ROC curve and AUC, with an AUC of 0.964 in the test set. The evaluation indexes show that the model has good prediction effect. Thus, using all the data, the final prediction model is constructed with the optimal parameter combinations.
And 4, early prediction is carried out according to the expression level of lincRNA which is characteristic of the patient:
and 4.1, normalizing the characteristic lincRNA expression data of the prediction sample, wherein the details are shown in a formula (18). The method randomly selects 10 samples for prediction, and eliminates the 10 samples when a final prediction model is constructed. The numbers of the 10 samples taken and the normalized characteristic lincRNA values are shown in table 3.
TABLE 3.10 sample numbers and values normalized for characteristic lincRNA
And 4.2, substituting the normalized lincRNA value of the prediction sample into the final prediction for prediction. A prediction of 1 indicates the presence of clear cell renal carcinoma, and a prediction of 0 indicates normal. The sample numbers of 10 cases, corresponding TCGA numbers, actual states and predicted results are shown in Table 4. The prediction results of 10 samples completely accord with the actual state, which shows that the invention can accurately predict the renal clear cell carcinoma in early stage.
TABLE 4.10 sample numbers, corresponding TCGA numbers, actual and predicted states
In conclusion, the characteristic lincRNA expression profile combination has high prediction accuracy, and can effectively predict renal clear cell carcinoma at early stage. In addition, the method has no platform dependency, and can predict data from various sources.
While the foregoing description shows and describes several preferred embodiments of the invention, it is to be understood, as noted above, that the invention is not limited to the forms disclosed herein, but is not to be construed as excluding other embodiments and is capable of use in various other combinations, modifications, and environments and is capable of changes within the scope of the inventive concept as expressed herein, commensurate with the above teachings, or the skill or knowledge of the relevant art. And that modifications and variations may be effected by those skilled in the art without departing from the spirit and scope of the invention as defined by the appended claims.
SEQUENCE LISTING
<110> institute of Buddha science and technology
<120> a characteristic lincRNA expression profile combination and early prediction method of renal clear cell carcinoma
<130>2020
<160>26
<170>PatentIn version 3.3
<210>1
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>1
cactgcagga aagggaccct gagcaaggga 30
<210>2
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>2
ggaaggacga gagggggcgc agacgaggga 30
<210>3
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>3
ctcagagaag ccctggccct cttttgaccc 30
<210>4
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>4
gtgccccctc ctccacctac cccaatcacc 30
<210>5
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>5
cactggctta aaaaaatttt ttatagcatc 30
<210>6
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>6
aaggtgctgc tgcggcaact ccatggcgat 30
<210>7
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>7
gctccgcagg atccccgcga ggaacagctg 30
<210>8
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>8
atcccgttag gaaacaacgg aggatggggc 30
<210>9
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>9
cagagggttc ccctggggtg aggctgtgct 30
<210>10
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>10
attgcacaat acagacattc ctaaattctg 30
<210>11
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>11
tcccctcgat tcttccccag acaaacccgg 30
<210>12
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>12
gagatccact tacacttctg aaaacgcaag 30
<210>13
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>13
gggattactc taatcaatat ccttcttgta 30
<210>14
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>14
agctcatata ttcaaaccat gcttgtgaaa 30
<210>15
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>15
agaggaggat gagagacaaa gaaaaaagtt 30
<210>16
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>16
aaatgcccac gataaacaaa taataaatag 30
<210>17
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>17
gcaagtatac aaatttattg aaaaggaaga 30
<210>18
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>18
gtgaacctag ctcagaagtt tgcaccatga 30
<210>19
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>19
cattctcaga gcacaaagac cccatgatct 30
<210>20
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>20
cactgggtcc tgagtctctt gttctggaag 30
<210>21
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>21
agctttcaaa gctgaccacg gccgtgcgca 30
<210>22
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>22
agttgctgag aggaggccag caggcaaatt 30
<210>23
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>23
gaaaagaacg ccgggggatt tggcttaaac 30
<210>24
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>24
acctgggccc ttctggtatc tcctgaatga 30
<210>25
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>25
ataaatgtgt tgtaacatga aacggtccca 30
<210>26
<211>30
<212>DNA
<213> Artificial sequence (Artificial sequence)
<400>26
ttccagggca gcccatcaca tcttagagct 30
Claims (6)
1. A combination of characteristic lincRNA expression profiles comprising AC002070.1, AC007114.1, AC015813.1, AC091271.1, AC091563.1, AC120049.1, AL355338.1, AP002360.1, C22orf34, CYTOR, DNAJC3-DT, EPB41L4A-AS1, FGF14-AS2, IQCH-AS1, LINC00240, LINC01503, LINC02381, LINC 15, MIR210HG, MIR4435-2HG, MUC20-OT1, PSMB8-AS1, PSMG3-AS1, SNHG15, URB1-AS1 and ZNF667-AS1, the nucleotide probe sequences of which are shown in SEQ ID NO. 1-26.
2. A method for the early prediction of clear cell carcinoma of the kidney based on the combination of characteristic lincRNA expression profiles of claim 1, comprising the steps of:
step 1, obtaining characteristic lincRNA stably and differentially expressed by a patient with renal clear cell carcinoma at an early stage;
step 2, selecting characteristic lincRNA expression data, and carrying out data standardization on each sample;
step 3, constructing an early prediction model for the standardized data by using a support vector machine;
step 4, carrying out early prediction according to the expression level of lincRNA (lincRNA) of the patient characteristics;
the method is for non-disease diagnostic and therapeutic purposes.
3. The method for predicting early renal clear cell carcinoma according to claim 2, wherein the characteristic lincrnas stably and differentially expressed in the patient with early renal clear cell carcinoma obtained in step 1 are specifically:
step 1.1, downloading transcriptome Data and clinical Data of tumor tissues and tissues beside renal clear cell carcinoma patients from a Genomic Data common Data Portal database, obtaining tumor tissue gene expression profile read counts values of the renal clear cell carcinoma patients, and carrying out logarithmic conversion;
step 1.2, selecting lincRNA with certain expression abundance, namely, taking the logarithm of the read counts of all the lincRNA to obtain the number n of samples, taking the total number of the screened lincRNA as m, v as the read counts of the lincRNA, and u as the expression value after taking the logarithm, then:
uij＝log2vij，i∈(1，n)，j∈(1，m) (1)
wherein i is the sample number, j is the lincRNA number, uijExpression value after taking logarithm of ith sample and jth lincRNA number, vijRead counts values for the ith sample, jth lincRNA number;
step 1.3, selecting renal clear cell carcinoma patients with disease stages of I and II, recording the patients as renal clear cell carcinoma early-stage patients, and recording the total number of the renal clear cell carcinoma early-stage patients as n';
step 1.4, selecting the lincRNA stably expressed in the tumor sample and the normal sample, namely the lincRNA with the coefficient of variation smaller than 0.2 in the tumor sample and the normal sample, setting mu as the expression mean value of the lincRNA in all samples, setting sigma as the standard deviation, and calculating the coefficient of variation according to the formula:
wherein j is the lincRNA number, cvIs the coefficient of variation, cvjCoefficient of variation, σ, for the j-th samplejStandard deviation for jth lincRNA numbering, μjThe expression average of lincRNA numbered for the jth lincRNA, set as m1For the total number of stably expressed lincrnas, the following are:
step 1.5, selecting lincRNA which is differentially expressed in a tumor sample and a normal sample; the log-taken expression values were used to calculate the log-taken fold change f of the lincrnas in tumor and normal samples, and the formula is:
wherein j is the lincRNA number, fjFold change for jth lincRNA numbering,. mu.1jExpression mean, μ, of tumor samples numbered for jth lincRNA2jThe expression mean of the normal sample numbered for the jth lincRNA;
the expression difference of lincRNA in tumor and normal samples was then compared using independent sample t-test, which was formulated as:
wherein n is1Is the number of tumor samples, n2Is a normal number of samples, mu1Mean expression of lincRNA in tumor samples, μ2Is the mean value of the expression of lincRNA in a normal sample,
the variance of lincRNA in the tumor sample,
lincRNA variance for normal samples;
correcting the p values obtained by all t tests by using a False Discovery Rate (FDR), wherein q is a value corrected by the FDR, and r is a p value in m1The sequenced positions in each lincRNA are:
wherein j is the lincRNA number;
finally, lincRNA with the absolute value of the fold change f larger than 1 and the q value smaller than or equal to 0.05 after FDR correction is selected and marked as characteristic lincRNA, and the total number of the characteristic lincRNA is set as m2Then, there are:
m2＝m1{|fj|≥1，qj≤0.05}，j∈(1，m1) (7)。
4. the method for early stage prediction of renal clear cell carcinoma of claim 2, wherein the characteristic lincRNA expression data in step 2 is selected and normalized for each sample according to the formula:
wherein i is the sample number, j is the characteristic lincRNA number,. mu.iThe mean, σ, of all characteristic lincRNA expression of the ith sampleiFor all characteristic lincRNA standard deviations, u, of the i-th sampleijTo take the characteristic lincRNA expression value after log, uij' is the normalized lincRNA value.
5. The early stage prediction method for renal clear cell carcinoma according to claim 2, wherein the step 3 uses a support vector machine to construct an early stage prediction model for the normalized data, specifically:
step 3.1, grouping all samples, dividing 80% of all samples into a training set and a verification set, and dividing the rest 20% of all samples into a test set; the training set and the verification set are used for 5-fold cross verification, namely the training set and the verification set are divided into 5 groups which are equal, one group is used as the verification set in sequence, and the other 4 groups are used as the training set; parameters are given, a training set is used for constructing a model, and a verification set is used for checking the accuracy of the model;
step 3.2, optimal parameter screening, wherein the parameter gamma in the SVM controls the width of a Gaussian kernel, C is a regularization parameter and limits the importance of each point, and a parameter grid is set as:
gamma＝[0.001，0.01，0.1，1，10，100](9)
C＝[0.001，0.01，0.1，1，10，100](10)
in the cross validation, a model is constructed by sequentially using the combination of every two parameters gamma and C, then a validation set is used for checking the accuracy of the model, for each parameter combination, 1 accuracy is generated in each validation of 5-fold cross validation, 5 accuracies are generated by carrying out 5 times of validation in total, and the parameter combination with the highest average accuracy of the 5 verifications is selected as the optimal parameter;
3.3, constructing a model by using the optimal parameters and data of the training set and the verification set, and finally evaluating the model by using the test set, wherein evaluation indexes comprise accuracy (accuracy), accuracy (precision), recall (call), specificity (specificity), F1 score (F1 score), Matthews Correlation Coefficient (MCC) and area under the Receiver Operating Curve (ROC) (AUC); in the test set, defining the tumor count as True Positive (TP), the tumor count as normal but predicted as False Positive (FP), the tumor count as true but predicted as normal False Negative (FN), the tumor count as normal but predicted as True Negative (TN); the above evaluation index calculation formula is:
the accuracy, recall, specificity, F1 score and AUC of the above assessment indices returned values between (0, 1); the higher the accuracy is, the higher the overall prediction efficiency of the model is; higher accuracy indicates that the class I error is smaller; higher recall indicates that a class II error is being made smaller; the high specificity indicates that few negative examples are mixed in the samples predicted to be positive examples; the F1 score is a comprehensive index and is a harmonic average of the accuracy rate and the recall rate; MCC is the correlation coefficient between observed and predicted binary classifications, returning a value between (-1, 1), where 1 represents perfect prediction, 0 represents no better than random prediction, -1 represents a complete disparity between prediction and observation; the higher AUC indicates the higher probability of the positive case predicted by the classifier, so that the closer the indexes are to 1, the better the overall prediction effect of the model is;
and 3.4, if the evaluation indexes are all larger than 0.9, the model has a better prediction effect, and then all data are used and the optimal parameter combination is used for constructing a final prediction model.
6. The early prediction method of renal clear cell carcinoma according to claim 2, wherein the early prediction in step 4 is performed according to the expression level of lincRNA characteristic to the patient, specifically:
step 4.1, standardizing the characteristic lincRNA expression data of the prediction sample, setting u as the characteristic lincRNA expression value of the prediction sample, setting mu as the average value of the characteristic lincRNA expression of the prediction sample, and setting sigma as the standard deviation of the characteristic lincRNA of the prediction sample, wherein the formula is as follows:
wherein j is the characteristic lincRNA numbering, uj' is the normalized lincRNA value;
and 4.2, substituting the normalized lincRNA value of the prediction sample into the final prediction to predict, wherein the prediction result is 1 to indicate that the patient has renal clear cell carcinoma, and the prediction result is 0 to indicate that the patient is normal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010775121.9A CN111808965A (en) | 2020-08-04 | 2020-08-04 | Characteristic lincRNA expression profile combination and early prediction method of renal clear cell carcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010775121.9A CN111808965A (en) | 2020-08-04 | 2020-08-04 | Characteristic lincRNA expression profile combination and early prediction method of renal clear cell carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111808965A true CN111808965A (en) | 2020-10-23 |
Family
ID=72864305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010775121.9A Withdrawn CN111808965A (en) | 2020-08-04 | 2020-08-04 | Characteristic lincRNA expression profile combination and early prediction method of renal clear cell carcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111808965A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114550815A (en) * | 2022-03-16 | 2022-05-27 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | Function prediction and screening method of glioblastoma lncRNA (long non-complementary ribonucleic acid) coding micro peptide |
-
2020
- 2020-08-04 CN CN202010775121.9A patent/CN111808965A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114550815A (en) * | 2022-03-16 | 2022-05-27 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | Function prediction and screening method of glioblastoma lncRNA (long non-complementary ribonucleic acid) coding micro peptide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111748632A (en) | Characteristic lincRNA expression profile combination and liver cancer early prediction method | |
| CN111748633A (en) | Characteristic miRNA expression profile combination and head and neck squamous cell carcinoma early prediction method | |
| CN112927757B (en) | Gastric cancer biomarker identification method based on gene expression and DNA methylation data | |
| CN105243296A (en) | Tumor feature gene selection method combining mRNA and microRNA expression profile chips | |
| CN111944902A (en) | Early prediction method of renal papillary cell carcinoma based on lincRNA expression profile combination characteristics | |
| CN115631789B (en) | Group joint variation detection method based on pan genome | |
| CN111944900A (en) | Characteristic lincRNA expression profile combination and early endometrial cancer prediction method | |
| Kontou et al. | Methods of analysis and meta-analysis for identifying differentially expressed genes | |
| CN111748634A (en) | Characteristic lincRNA expression profile combination and early prediction method of colon cancer | |
| CN111733251A (en) | Characteristic miRNA expression profile combination and early prediction method of renal clear cell carcinoma | |
| CN111763738A (en) | Characteristic mRNA expression profile combination and liver cancer early prediction method | |
| CN111808965A (en) | Characteristic lincRNA expression profile combination and early prediction method of renal clear cell carcinoma | |
| CN114203256A (en) | MIBC typing and prognosis prediction model construction method based on microbial abundance | |
| CN111850124A (en) | Characteristic lincRNA expression profile combination and lung squamous carcinoma early prediction method | |
| CN116312800A (en) | Lung cancer characteristic identification method, device and storage medium based on circulating RNA whole transcriptome sequencing in blood plasma | |
| CN113862351A (en) | Kit and method for identifying extracellular RNA biomarkers in body fluid sample | |
| CN111733252A (en) | Characteristic miRNA expression profile combination and early gastric cancer prediction method | |
| CN111793692A (en) | Characteristic miRNA expression profile combination and lung squamous carcinoma early prediction method | |
| CN111718996A (en) | Characteristic lincRNA expression profile combination and early gastric cancer prediction method | |
| CN115035951A (en) | Mutation signature prediction method and device, terminal equipment and storage medium | |
| CN111944901A (en) | Characteristic mRNA expression profile combination and renal papillary cell carcinoma early prediction method | |
| Mythili et al. | CTCHABC-hybrid online sequential fuzzy Extreme Kernel learning method for detection of Breast Cancer with hierarchical Artificial Bee | |
| CN109887543B (en) | Differential methylation site recognition method for low methylation level | |
| CN112760375A (en) | Characteristic miRNA expression profile combination and endometrial cancer early-stage prediction method | |
| CN111944898A (en) | Characteristic mRNA expression profile combination and renal clear cell carcinoma early prediction method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20201023 |